CIBC Bancorp USA Inc. Invests $24.42 Million in Gilead Sciences, Inc. $GILD

CIBC Bancorp USA Inc. bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the third quarter, HoldingsChannel.com reports. The fund bought 219,986 shares of the biopharmaceutical company’s stock, valued at approximately $24,418,000.

Several other hedge funds have also bought and sold shares of GILD. Csenge Advisory Group increased its holdings in shares of Gilead Sciences by 319.0% in the third quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company’s stock valued at $2,375,000 after purchasing an additional 16,288 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its stake in shares of Gilead Sciences by 52.1% during the 3rd quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company’s stock worth $8,713,000 after buying an additional 26,882 shares during the last quarter. Cookson Peirce & Co. Inc. boosted its holdings in shares of Gilead Sciences by 249.1% during the 3rd quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company’s stock worth $1,115,000 after buying an additional 7,168 shares during the period. Railway Pension Investments Ltd grew its stake in Gilead Sciences by 3.1% in the 3rd quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company’s stock valued at $157,139,000 after buying an additional 42,200 shares during the last quarter. Finally, TriaGen Wealth Management LLC bought a new position in Gilead Sciences in the 3rd quarter valued at about $1,274,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total value of $617,500.00. Following the sale, the director owned 8,920 shares of the company’s stock, valued at approximately $1,101,620. This trade represents a 35.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $144.23, for a total value of $432,690.00. Following the transaction, the chief financial officer directly owned 179,191 shares of the company’s stock, valued at $25,844,717.93. This trade represents a 1.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 309,280 shares of company stock valued at $44,068,850. 0.27% of the stock is owned by insiders.

Gilead Sciences Stock Down 2.2%

GILD stock opened at $141.29 on Thursday. Gilead Sciences, Inc. has a 52 week low of $93.37 and a 52 week high of $157.29. The business has a 50-day simple moving average of $141.96 and a 200 day simple moving average of $127.51. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. The company has a market cap of $175.40 billion, a PE ratio of 20.87, a price-to-earnings-growth ratio of 1.89 and a beta of 0.37.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The firm had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same period in the prior year, the company posted $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 2.3%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Friday, March 13th. Gilead Sciences’s payout ratio is 48.45%.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Quarterly beat, raised guidance and dividend increase provide fundamental support — Gilead reported $1.86 EPS (vs. $1.83 est.), $7.93B revenue (vs. $7.68B est.), set FY‑2026 EPS guidance of $8.45–$8.85 and raised the quarterly dividend to $0.82. Those elements support longer‑term upside.
• Positive Sentiment: M&A/sector takeover chatter (Arcellx coverage) is reviving speculation that Gilead may pursue deals to bolster its cell‑therapy/oncology pipeline — a catalyst investors treat as strategic upside. Fool: Arcellx / takeover-related coverage
• Neutral Sentiment: Unusual options activity flagged by scanners — heightened option flow can signal hedging or speculative bets; it’s ambiguous until directional put/call skew and volume patterns solidify. Barchart: options activity
• Neutral Sentiment: Analysts show mixed/contrasting views — some firms have raised targets and reiterated buys while others are more cautious, so research flow is creating both support and headlines that can move sentiment. Globe and Mail: analysts conflicting
• Neutral Sentiment: New coverage of potential CAR‑T competitors (Estrella/ESLA) is worth watching but is not an immediate direct threat to Gilead’s larger, diversified franchise — more a sector development. Yahoo: ESLA coverage
• Negative Sentiment: Insider selling by senior executives — Johanna Mercier and CFO Andrew D. Dickinson each sold 3,000 shares (average ~$144.23) recently; multiple insider sales can sour near‑term sentiment even if part of planned diversification. InsiderTrades: insider sales
• Negative Sentiment: Recent headlines and retail coverage are bearish — pieces arguing to “avoid GILD” are amplifying outflows/weakness among some investors and may pressure the intraday move. Yahoo: 3 Reasons to Avoid GILD
• Negative Sentiment: Market‑coverage note reporting Gilead fell more than the broader market today — a short‑term confirmation of downward price pressure that may trigger additional technical selling. Zacks: GILD falls more than market

Wall Street Analyst Weigh In

GILD has been the subject of several research reports. TD Cowen raised their price objective on shares of Gilead Sciences from $145.00 to $160.00 and gave the stock a “buy” rating in a research report on Wednesday, February 11th. Wolfe Research increased their target price on Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a research note on Thursday, February 12th. Citigroup reissued a “buy” rating on shares of Gilead Sciences in a report on Friday, March 6th. Mizuho boosted their price target on Gilead Sciences from $140.00 to $170.00 and gave the company an “outperform” rating in a research note on Wednesday, February 18th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $170.00 price objective on shares of Gilead Sciences in a report on Monday, February 23rd. Twenty-four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $157.62.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.